AbCellera completes pricing of $200 million offering, files final prospectus supplement
The company detailed final offering economics and closing terms, with the deal expected to close August 14, 2026.
SEC filing (3)
Latest
3 stories
Thursday, August 13
Monday, August 10
AbCellera reports positive Phase 2 results for menopause drug ABCL635
The antibody hit its primary endpoints in a placebo-controlled trial, cutting hot flash frequency and severity after one dose.
SEC filing (3)
Wednesday, July 29
AbCellera to lead T-cell engager discovery for Vertex under new autoimmune disease pact
Vertex will fund R&D and hold development and commercialization rights, while AbCellera receives upfront payments and is eligible for milestones and royalties.
SEC filing